Navigation Links
ASA404 in Medical Technology

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherap...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

...squamous and non-squamous non-small cell lung cancer patients receiving asa404 (Abstract #8072: Sunday, June 1, 2008; 2:00 PM-6:00 PM CDT). Novartis...with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). asa404 is an investigational small-molecule Tumor-VDA that selectively disrupts ex...
ASA404 in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...in Prostate Cancer II-53 Isis and OncoGenex Reveals Positive results of OGX-011 Molecule in HRPC II-53 Antisoma Completes Phase 2 Study of asa404 in Prostate Cancer II-53 Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer II-54 Ambrilia Unveils Resu...
ASA404 in other areas

Vadimezan - Wikipedia, the free encyclopedia

Vadimezan or ASA404 is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.

Novartis Oncology Research: ASA404 For Lung Cancer

Read information about ASA404, a Novartis Oncology investigational cancer treatment that disrupts established tumor vasculature, inhibiting tumor blood flow and ...

ASA404 Vascular Disrupting Agent for Solid Tumours - Drug Development ...

Project on the ASA404 vascular disrupting agent for solid tumours by Antisoma and Novartis. ... Novartis subsequently acquired worldwide rights to ASA404 in 2007. ...

Positive data on Antisoma's ASA404 presented at ASCO | Reuters

LONDON, UK, Jun 01 (MARKET WIRE) -- London, UK, and Chicago, IL, 1 June 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that two presentations supporting ASA404 ...

starting a Phase III trial for the drug, ASA404

ASA404 ... Novel mechanism of action of ASA404 disrupts existing blood supply to tumors ... ASA404 is one of six novel oncology compounds Novartis is developing for ...

ATTRACT Clinical Trial – Antivascular Targeted Therapy: Researching ...

Learn about ATTRACT clinical trial from Novartis Oncology, and investigational cancer treatment: Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment.
Other Tags
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen an increasing ... care model, where the primary care physician dictates and the patient obeys. Instead, our ... about their health issues and empowered to choose their own treatment options. , Recognizing ...
(Date:9/3/2015)... Kingston, NY (PRWEB) , ... September 03, 2015 , ... ... on iTunes, April Hannah & Michael Habernig from Path 11 Productions have had great ... This new age podcast has featured Hay House authors, Teal Swan who is the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa ... health professionals out there. His perspective on internal medicine keeps patients happy and healthy, ... healthy is important regardless of the season, but even more so in the fall, ...
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), ... retreats geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. ... developing a whole mind-body approach to fitness - we are much more than a ...
Breaking Medicine News(10 mins):Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:TAC Introduces New Retreats for Fall Fitness 2
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... , Aug. 12, 2015  New research ... can attack Android phones to steal users, fingerprints. ... increasing availability of fingerprint scanners on mobile devices, ... concern. To secure biometrics on mobile devices, HYPR ... augment these convenient authentication systems with strong cryptographic ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2
Other Contents